USPSTF Recommends Against Thyroid Cancer Screening

Share this content:
The USPSTF stated that there was inadequate direct evidence for the benefits of screening.
The USPSTF stated that there was inadequate direct evidence for the benefits of screening.

The US Preventive Services Task Force (USPSTF) recommends against screening for thyroid cancer among asymptomatic adults.1

The USPSTF stated that there was inadequate direct evidence for the benefits of screening. Any benefits associated with screening and treatment vs no screening appeared to be small.

There was also inadequate direct evidence of harms of screening, though the USPSTF stated that the overall harm is likely at least moderate.

“Clinicians should understand the evidence but individualize decision making to the specific patient or situation,” wrote the USPSTF.

The Grade D recommendation statement and evidence summary are published in JAMA.2,3

RELATED: Regorafenib Phase 2 Trial for Metastatic Medullary Thyroid Cancer

The rarity of thyroid cancer, according to the USPSTF's article in JAMA, as well as the “apparent” lack of benefit for patients who are treated for their disease rather than monitored, were factors leading to this recommendation.

More information can be found on the USPSTF website.

Reference

  1. US Preventive Services Task Force. Thyroid Cancer: Screening. https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/thyroid-cancer-screening1. Accessed May 9, 2017.
  2. US Preventive Services Task Force. Screening for thyroid cancer: US Preventative Services Task Force Recommendation Statement. JAMA. 2017;317:1882-7.
  3. Lin JS, Aiello Bowles EJ, Williams SB, Morrison CC. Screening for thyroid cancer: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2017;317:1888-903.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters